CMS Open Payments · Program Year 2024
Tempus AI, Inc
Tempus AI, Inc reported $683,535.58 across General Payments, Research, and Ownership to 14,627 physicians and teaching hospitals across 14,627 transactions.
- $683.5K
- All-tracks total
- 14,627
- Transactions
- 14,627
- Recipients
- #697
- of 1,925 companies
Tempus AI, Inc reported $683,535.58 across all CMS Open Payments tracks (General + Research + Ownership) to 14,627 physicians and teaching hospitals in Program Year 2024 - ranking #697 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $683,535.58, averaging $46.73 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer tempus-ai-inc Tempus AI, Inc
$683.5K · #697/1,925 · 0.0% industry · PY2024
- TOT $683.5K
- RANK #697
- SHARE 0.0%
- TXN 14,627
- RCP 14,627
- CAT 3
- GEN $683.5K
- TOP1 6.1%
- PY 2024
Volume peers
Nearest volume peer: SNAP Diagnostics LLC ($687.2K)
Tempus AI, Inc sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Tempus AI, Inc
$683,535.58: that is what Tempus AI, Inc reported in payments to 14,627 physicians and teaching hospitals during Program Year 2024, spread across 14,627 transactions ($46.73 per transaction, $46.73 per recipient). The company sits at rank #697 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
14,469 transactions worth $430.9K make "Food and Beverage" the top general-payment category in the 3-category breakdown below, 63.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Food and Beverage" leads Tempus AI, Inc's 3-category general-payment breakdown at $430.9K, 63.0% of the reported total.
How Tempus AI, Inc divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $430.9K | 14,469 | 63.0% |
| Consulting Fee | $239.8K | 113 | 35.1% |
| Travel and Lodging | $12.9K | 45 | 1.9% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $121,651.91 (17.8%) of $683,535.58 in this company's General Payments records across 7,999 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Tempus AI, Inc
The five named recipients with the highest reported General Payments from this company
- 1
Mahran Shoukier
$41,943.88 across 14 reported transactions
- 2
Amol Rao
$35,126.37 across 5 reported transactions
- 3
Bobby Chawla
$20,886.86 across 33 reported transactions
- 4
Anthony Mato
$11,975.00 across 8 reported transactions
- 5
Vijay Gunuganti
$11,719.80 across 8 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Tempus AI, Inc's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Tempus AI, Inc.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Tempus AI, Inc.
Showing 6 of 1,924 companies with CMS-reported payment data.
Kaneka Medical America LLC
Synapse Surgical LLC
Extremity Medical
Verathon Inc.
Teleflex Incorporated
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.